Healthcare Industry News: Baxter International
News Release - September 7, 2006
Baxter Names Peter Nicklin Corporate Vice President and President, Baxter EuropeDEERFIELD, Ill., Sept. 7 (HSMN NewsFeed) -- Baxter International Inc. (NYSE: BAX ) today announced that Peter Nicklin has been named corporate vice president of Baxter World Trade Corporation and president of Baxter Europe, effective October 1, 2006. Nicklin will be responsible for the company's European operations, which had revenues totaling over $3 billion in 2005. Nicklin, 43, will be based in Zurich, Switzerland, reporting to John J. Greisch, corporate vice president and president of Baxter's international operations.
"With his significant international experience and outstanding track record within the pharmaceutical and medical device industries, Peter is ideally suited to lead our European organization," said Greisch. "His talents in developing businesses and people will help drive continued growth for Baxter across Europe."
Nicklin joins Baxter from Bayer AG where he served as president of the Animal Health Division, board member of Bayer HealthCare AG and regional head of Bayer HealthCare's business in Asia Pacific.
Prior to joining Bayer, Nicklin was responsible for the Western and Central European pharmaceutical businesses of Novartis AG. He also held several general and executive management positions for Bristol-Myers Squibb Company in Europe and Asia. Nicklin qualified as a chartered accountant while with PricewaterhouseCoopers in London after earning a bachelor's degree from Lancaster University in England.
Baxter World Trade Corporation is a subsidiary of Baxter International Inc. (NYSE: BAX ). Baxter International Inc., through its subsidiaries, assists healthcare professionals and their patients with treatment of complex medical conditions, including cancer, hemophilia, immune disorders, kidney disease and trauma. The company applies its expertise in medical devices, pharmaceuticals and biotechnology to make a meaningful difference in patients' lives.
Issuer of this News Release is solely responsible for its
Please address inquiries directly to the issuing company.